Envision the Future and Take on the Power of Computing with GIGABYTE at COMPUTEX 2022
GIGABYTE, a world leader in computer technology, will be presenting “Power of Computing” as its theme of the year, and exhibiting its leading products and solutions designed for various industries and fields in the upcoming COMPUTEX Taipei.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005640/en/
Envision the Future and Take on the Power of Computing with GIGABYTE at COMPUTEX 2022
GIGABYTE has curated its presentation around the theme “Power of Computing” to demonstrate that, everything from the cloud to the edge, from team collaboration to individual creation, from business applications to personal use, computing done by servers in data centers to process massive data and embedded systems in IoT and personal computers to render real-time information is the key behind groundbreaking innovations that appear in the fields of AI, cloud deployment, smart technologies, and digital content creation, etc.
Data Center is an integral part of making technological breakthroughs. GIGABYTE is a trusted pioneer in developing new server products for developers, and worked on software integrations to provide product solutions that are in line with the future of the digital age. GIGABYTE also works closely with vendors in early stages of HPC server platform development, so that system integration and optimization of SmartNICs and GPGPUs allow for heterogeneous architecture in servers to provide application-specific computing acceleration the higher computation and efficiency. In addition to supporting x86 applications using AMD and Intel processors, GIGABYTE also offers the choice of ARM servers that provide consistent data processing and encoding from the user’s terminal to edge, which not only enhances an agile response but also accelerates the development of innovations in the edge computing-piloted 5G era.
GIGABYTE is dedicated to use computing performance to accelerate innovation and advance quality of life, and has devoted effort into development of various cooling methods that includes launching products with direct liquid cooling and immersion cooling technologies to reduce the environmental impact of increased heat generated by data centers.
In the new digital age driven by AI-enabled applications, GIGABYTE has coupled its servers with MyelinTe's MLSteam platform to cluster all computing servers, storage and management nodes to facilitate resource allocation, monitoring and management, and effectively maximize resource utilization. GIGABYTE further expands its hardware experience and expertise by releasing embedded computers into everyday applications such as the fields of self-driving cars and the Internet of Vehicles. GIGABYTE's ADCU series can process massive data and make vehicle-control decisions on a real-time basis; and T-BOX can handle data and mutual communications between on-road vehicles, which is an ideal solution suitable for commercial fleet management.
Computing powers the engine for technological progression, not only to enabling successes in businesses, but also providing exhilarating personal experiences. GIGABYTE exhibits an NVIDIA Omniverse™ virtual collaboration scenario with a host-client setup using its high-performance W771-Z00 workstation and visual-spectacle BRIX mini PC; an awe-inspiring gaming showcase of flagship gaming solutions powered by Intel 12th gen processors, iF Design award-winning motherboards and monitor, and AMD Socket AM5 motherboards with advanced design and extensive features of PCIe 5.0 graphics slot and m.2 Gen5 interface; and GIGABYTE's creator/gaming laptops provide high performance with premium visual experience, with its newest flagship gaming laptop featuring the 12th Gen Intel® Core™ i9 HX series processor, offer a glimpse at the Metaverse potential.
From May 24th to 27th, GIGABYTE is primed, with an array of product solutions and applications, and ready to exhibit its hardware expertise and technology know-how, which possess the computing performance to accelerate technology innovations and uphold its vision to “Upgrade Your Life”
GIGABYTE @ COMPUTEX 2022 - https://gbte.tech/CX22
More About GIGABYTE enterprise: https://www.gigabyte.com/enterprise
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220519005640/en/
Contact information
Media: Michael Pao brand@gigabyte.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new